It's Time to Move Forward


Prosigna is now included in international clinical practice guidelines.

Managing patients with early-stage breast cancer begins with a highly accurate assessment of risk.

Proceed with Confidence

Prosigna uses the PAM50 gene signature to translate tumor biology into your patient's individualized prognostic score.

Learn about PAM50

Advanced technology generates precise, reproducible prognostic information in local qualified laboratories.

How Prosigna works

Prosigna reliably identifies your patient's 10-year risk of distant recurrence.

Clinical validation data

Prosigna® is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.

Prosigna Breast Cancer Prognostic Gene Signature Assay for use on the nCounter® Dx Analysis System is 510(k) cleared and CE-marked for in vitro diagnostic use in the United States and EU, respectively. See Package Insert for details